Abiopharma

Edgewise Therapeutics Inc (EWTX) Reports Q2 2022 Financial Results Edgewise Therapeutics Inc (EWTX) announced its financial results for the period ending Q2 2022. Key Financial Highlights:

• Revenue: Not disclosed
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 265833
  • 5506 data in individuals with BMD, a disorder for which there are no approved treatments,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “Based on these exciting results and the potential to bring EDG
  • 5506 to the BMD and DMD communities, we are working with urgency on behalf of patients to initiate our Phase 2 trials in BMD in the coming weeks and in DMD later this year.” Recent Highlights EDG
  • 5506 ARCH Study Completed Enrollment The Company completed enrollment in the ARCH open label study that is evaluating EDG
    • targeting inherited hypertrophic cardiomyopathy (HCM). Further, the team is exploring the potential of this novel mechanism across other cardiac disorders. Preliminary preclinical studies offer evidence that the EDG-002 program has the potential to yield molecules that could become a new standard of care for the treatment of HCM. We plan to initiate IND-enabling studies in 2022
    • targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, Twitter andFacebook. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933